B. Riley Has Negative Outlook of LifeMD FY2025 Earnings

LifeMD, Inc. (NASDAQ:LFMD) – Stock analysts at B. Riley dropped their FY2025 earnings per share (EPS) estimates for LifeMD in a research report issued on Tuesday, November 18th. B. Riley analyst A. Schock now anticipates that the company will post earnings per share of ($0.27) for the year, down from their prior estimate of ($0.14). B. Riley has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.56) per share. B. Riley also issued estimates for LifeMD’s Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.27) EPS.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Monday, November 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The firm had revenue of $60.17 million for the quarter, compared to analyst estimates of $62.07 million. During the same period in the previous year, the company earned $0.09 EPS. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

A number of other analysts also recently commented on the company. KeyCorp decreased their target price on LifeMD from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Wednesday. HC Wainwright decreased their price objective on shares of LifeMD from $13.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday. Mizuho lowered their price objective on shares of LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday. Zacks Research upgraded shares of LifeMD from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Finally, BTIG Research reduced their price target on shares of LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.43.

LifeMD Trading Up 3.8%

Shares of LifeMD stock opened at $3.85 on Friday. The company has a 50-day moving average of $5.88 and a two-hundred day moving average of $8.59. LifeMD has a 12-month low of $3.43 and a 12-month high of $15.84. The stock has a market cap of $185.34 million, a PE ratio of -22.65 and a beta of 1.57.

Insider Activity

In related news, insider Nicholas P. Alvarez sold 75,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total transaction of $444,000.00. Following the transaction, the insider owned 605,000 shares of the company’s stock, valued at approximately $3,581,600. This represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 18.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of LifeMD by 6.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,226,871 shares of the company’s stock worth $15,120,000 after purchasing an additional 140,749 shares during the period. Royce & Associates LP increased its stake in LifeMD by 3.5% in the first quarter. Royce & Associates LP now owns 1,155,231 shares of the company’s stock valued at $6,284,000 after purchasing an additional 39,240 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in LifeMD by 5.4% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 981,894 shares of the company’s stock worth $5,342,000 after buying an additional 50,600 shares during the period. Geode Capital Management LLC lifted its position in LifeMD by 7.9% during the second quarter. Geode Capital Management LLC now owns 925,173 shares of the company’s stock worth $12,603,000 after buying an additional 67,440 shares during the period. Finally, Jump Financial LLC boosted its stake in LifeMD by 205.0% in the 2nd quarter. Jump Financial LLC now owns 515,052 shares of the company’s stock worth $7,015,000 after buying an additional 346,171 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.